RxDoctor Payments Data

Sarah Knoth

Family · Muncie, INNPI 1083245088

Payments from drug & device makers

$2,658in general payments, 2019–2025

Across 56 payments — averaging $47.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$416
  • Novo Nordisk$332
  • Teleflex LLC$145
  • Lilly USA, LLC$128
  • Biohaven Pharmaceutical Holding Company Ltd.$105
  • plus $192 from 7 others

What the payments were for

  • Speaking & faculty fees$98037%
  • Food & beverage$1,67963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,658 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$42,044
Medicare patients
212
Services billed
731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide47$58,891
OzempicSemaglutide26$32,958
EliquisApixaban25$26,062
FarxigaDapagliflozin Propanediol18$18,481
JardianceEmpagliflozin19$12,022
XareltoRivaroxaban13$10,612
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,232
SymbicortBudesonide/Formoterol Fumarate11$3,583
SynthroidLevothyroxine Sodium33$2,815
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen99$2,716
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$2,504
Atorvastatin Calcium192$1,751
Albuterol Sulfate HfaAlbuterol Sulfate44$1,256
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$1,238
Duloxetine Hcl28$1,123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$128$58,89147 claims
Novo NordiskOzempic$332$32,95826 claims
AstraZenecaFarxiga, Symbicort$416$22,06429 claims
Boehringer IngelheimJardiance$12$12,02219 claims
AbbVieSynthroid$1,341$2,81533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →